MXPA04001933A - Composicion farmaceutica que comprende lumiracoxib. - Google Patents

Composicion farmaceutica que comprende lumiracoxib.

Info

Publication number
MXPA04001933A
MXPA04001933A MXPA04001933A MXPA04001933A MXPA04001933A MX PA04001933 A MXPA04001933 A MX PA04001933A MX PA04001933 A MXPA04001933 A MX PA04001933A MX PA04001933 A MXPA04001933 A MX PA04001933A MX PA04001933 A MXPA04001933 A MX PA04001933A
Authority
MX
Mexico
Prior art keywords
tablets
lumiracoxib
administration
pharmaceutical composition
fluoroanilino
Prior art date
Application number
MXPA04001933A
Other languages
English (en)
Inventor
Abdulquadar Karnachi Anees
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MXPA04001933A publication Critical patent/MXPA04001933A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describe aqui tabletas y metodos de tratamiento que comprenden la administracion de dichas tabletas. Las tabletas son tabletas de liberacion inmediata, que contienen aproximadamente 400 mg de acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico o una sal de eI farmaceuticamente aceptable; en donde el acido 5-metil-2- (2'-cloro-6'-fluoroanilino)fenilacetico o una sal de el farmaceuticamente aceptable constituyen entre el 60 por ciento y el 70 por ciento en peso de la tableta. Los metodos comprenden administrar las tabletas de la invencion a individuos que necesiten de la administracion de dichas tabletas.
MXPA04001933A 2001-08-31 2002-08-30 Composicion farmaceutica que comprende lumiracoxib. MXPA04001933A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31638901P 2001-08-31 2001-08-31
PCT/EP2002/009701 WO2003020261A1 (en) 2001-08-31 2002-08-30 Pharmaceutical composition comprising lumiracoxib

Publications (1)

Publication Number Publication Date
MXPA04001933A true MXPA04001933A (es) 2004-06-15

Family

ID=23228840

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04001933A MXPA04001933A (es) 2001-08-31 2002-08-30 Composicion farmaceutica que comprende lumiracoxib.

Country Status (30)

Country Link
US (2) US20030114527A1 (es)
EP (1) EP1425005B1 (es)
JP (1) JP4636796B2 (es)
KR (1) KR100895551B1 (es)
CN (1) CN100406008C (es)
AR (1) AR036312A1 (es)
AT (1) ATE324883T1 (es)
AU (1) AU2002331094B2 (es)
BR (1) BR0212155A (es)
CA (1) CA2456604C (es)
CO (1) CO5560554A2 (es)
CY (1) CY1106137T1 (es)
DE (1) DE60211183T2 (es)
DK (1) DK1425005T3 (es)
EC (1) ECSP044986A (es)
ES (1) ES2263813T3 (es)
HK (1) HK1087336A1 (es)
HU (1) HUP0401429A2 (es)
IL (1) IL160375A0 (es)
MX (1) MXPA04001933A (es)
MY (1) MY137516A (es)
NO (1) NO20040860L (es)
NZ (1) NZ531342A (es)
PE (1) PE20030323A1 (es)
PL (1) PL367464A1 (es)
PT (1) PT1425005E (es)
RU (1) RU2329801C2 (es)
SI (1) SI1425005T1 (es)
WO (1) WO2003020261A1 (es)
ZA (1) ZA200400877B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020351A1 (es) * 2000-09-11 2002-06-14 Novartis Ag Composiciones farmaceuticas que comprenden acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico como inhibidor de la ciclooxigenasa-2
GB0201520D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Pharmaceutical uses
PL370907A1 (en) * 2002-03-07 2005-05-30 Novartis Ag Pharmaceutical compositions
MX2011001341A (es) 2008-08-19 2011-03-29 Xenoport Inc Prodrogas de metil hidrogeno fumarato, sus composiciones farmaceuticas, y metodos de uso.
US20140093563A1 (en) * 2011-06-13 2014-04-03 Ranbaxy Laboratories Limited Febuxostat compositions
US10952968B2 (en) 2012-05-14 2021-03-23 Shionogi & Co., Ltd. Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives
US10945984B2 (en) 2012-08-22 2021-03-16 Arbor Pharmaceuticals, Llc Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
AU2013305684B2 (en) 2012-08-22 2016-11-24 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
EA018867B1 (ru) * 2012-11-01 2013-11-29 Лаборатория Тютор С.А.С.И.Ф.И.А. Способ получения фармацевтической композиции и продукт способа
WO2014160633A1 (en) 2013-03-24 2014-10-02 Xenoport, Inc. Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
WO2014205392A1 (en) 2013-06-21 2014-12-24 Xenoport, Inc. Cocrystals of dimethyl fumarate
JP2016534133A (ja) 2013-09-06 2016-11-04 ゼノポート，インコーポレイティド （ｎ，ｎ−ジエチルカルバモイル）メチル メチル（２ｅ）ブト−２−エン−１，４−ジオエートの結晶形態、その合成方法及び使用
KR20160107254A (ko) * 2014-01-10 2016-09-13 존슨 앤드 존슨 컨수머 인코포레이티드 고주파 및 손실 코팅된 입자를 사용하여 정제를 제조하는 방법
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
EP3162362A1 (de) * 2015-10-30 2017-05-03 Dr. Falk Pharma Gmbh Optimierte mesalazinhaltige hochdosistablette
US10493026B2 (en) 2017-03-20 2019-12-03 Johnson & Johnson Consumer Inc. Process for making tablet using radiofrequency and lossy coated particles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2163111C (en) * 1993-06-08 2010-10-26 Peter Heinrich Stahl Process for the preparation of an oral solid dosage form containing diclofenac
JPH11512754A (ja) * 1996-05-17 1999-11-02 メルク エンド カンパニー インコーポレーテッド シクロオキシゲナーゼ―２媒介疾患の一日一回治療用組成物
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
PE20020351A1 (es) * 2000-09-11 2002-06-14 Novartis Ag Composiciones farmaceuticas que comprenden acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico como inhibidor de la ciclooxigenasa-2

Also Published As

Publication number Publication date
JP2005520785A (ja) 2005-07-14
DK1425005T3 (da) 2006-09-04
BR0212155A (pt) 2004-07-13
PT1425005E (pt) 2006-09-29
CO5560554A2 (es) 2005-09-30
PL367464A1 (en) 2005-02-21
CN100406008C (zh) 2008-07-30
ZA200400877B (en) 2004-11-01
EP1425005A1 (en) 2004-06-09
EP1425005B1 (en) 2006-05-03
AR036312A1 (es) 2004-08-25
DE60211183D1 (de) 2006-06-08
HUP0401429A2 (hu) 2004-11-29
DE60211183T2 (de) 2007-02-01
HK1087336A1 (en) 2006-10-13
AU2002331094B2 (en) 2006-08-31
KR100895551B1 (ko) 2009-04-29
IL160375A0 (en) 2004-07-25
JP4636796B2 (ja) 2011-02-23
NO20040860L (no) 2004-04-22
CY1106137T1 (el) 2011-06-08
ECSP044986A (es) 2004-04-28
PE20030323A1 (es) 2003-05-12
KR20040031019A (ko) 2004-04-09
US20030114527A1 (en) 2003-06-19
CA2456604C (en) 2011-02-08
US20070231382A1 (en) 2007-10-04
ATE324883T1 (de) 2006-06-15
ES2263813T3 (es) 2006-12-16
CA2456604A1 (en) 2003-03-13
MY137516A (en) 2009-02-27
WO2003020261A1 (en) 2003-03-13
RU2329801C2 (ru) 2008-07-27
NZ531342A (en) 2005-09-30
CN1728993A (zh) 2006-02-01
RU2004109920A (ru) 2005-04-20
SI1425005T1 (sl) 2006-12-31

Similar Documents

Publication Publication Date Title
HK1087336A1 (en) Pharmaceutical composition comprising lumiracoxib
BG106251A (en) Levodopa (carbidopa) entacapone pharmaceutical preparation
AU1227899A (en) Osmotic medicament releasing system
BG105173A (en) Novel salt form of pantoprazole
DE60121570D1 (de) Oral anzuwendende schnell zerfallende feste darreichungsformen
IL186655A0 (en) Mucoadhesive xyloglucan-containing formulations useful in medical devices and in pharmaceutical formulations
FI20011852A (fi) Menetelmä fluoksetiinia tai sen happoadditiosuolaa sisältävän dispergoituvan tabletin valmistamiseksi
IS7006A (is) Tvívetnis 3-piperidínóprópíófenon og lyf sem innihalda téð efnasambönd
CA2411882A1 (en) Solid valsartan pharmaceutical compositions
CA2383212A1 (en) Controlled release oral dosage suitable for oral administration
ES2130081B1 (es) Comprimido de maleato de trimebutina con recubrimiento laminar.
CA2416771A1 (en) 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid for treatment of cox-2 dependent disorders
MXPA04003506A (es) Metodo para la preparacion de una composicion farmaceutica que comprende acido 5-aminosalicilico para el uso en el tratamiento de la colitis ulcerativa y de la enfermedad de crohn.
MY137570A (en) Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis crohn's disease
PL377683A1 (pl) System terapeutyczny zawierający amoksycylinę i kwas klawulanowy
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone
WO2003099214A3 (en) Biguanide formulations
GEP20043377B (en) Pharmaceutical Complex
HK1075654A1 (en) Hyperforin derivatives, the use thereof and formulations containing them
HK1075390A1 (en) Citalopram for the treatment of elevated blood pressure
WO2004073627A3 (en) Novel therapeutic method and compositions for topical administration
AU2001295839A1 (en) Use of agents active against candida in the treatment of disorders of the oral and intestinal mucosa
HUP0200148A2 (hu) N-(3',4'-dimetoxi-cinnamoil)antranilsav alkalmazása szívkoszorúér-műtéttel kapcsolatos cardiovascularis események megelőzésére vagy mérséklésére
TH65639A (th) องค์ประกอบทางเภสัชกรรม

Legal Events

Date Code Title Description
FG Grant or registration